Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 94 entries
Sorted by: Best Match Show Resources per page
Influence of Body Weight Category on Outcomes in Candidemia Patients Treated With Anidulafungin.

Journal of pharmacy practice

Hutton M, Kenney RM, Vazquez JA, Davis SL.
PMID: 32648506
J Pharm Pract. 2020 Jul 10;897190020938219. doi: 10.1177/0897190020938219. Epub 2020 Jul 10.

BACKGROUND: Case reports and pharmacokinetic data suggest off-label echinocandin dosing may be needed to reach adequate serum concentrations in obese patients. Few outcome studies exist evaluating this population.OBJECTIVES: Of this study were to (1) determine the association of body...

Cite
Hutton M, Kenney RM, Vazquez JA, et al. Influence of Body Weight Category on Outcomes in Candidemia Patients Treated With Anidulafungin. J Pharm Pract. 2020;897190020938219doi: 10.1177/0897190020938219.
Hutton, M., Kenney, R. M., Vazquez, J. A., & Davis, S. L. (2020). Influence of Body Weight Category on Outcomes in Candidemia Patients Treated With Anidulafungin. Journal of pharmacy practice, 897190020938219. https://doi.org/10.1177/0897190020938219
Hutton, Mary, et al. "Influence of Body Weight Category on Outcomes in Candidemia Patients Treated With Anidulafungin." Journal of pharmacy practice vol. (2020): 897190020938219. doi: https://doi.org/10.1177/0897190020938219
Hutton M, Kenney RM, Vazquez JA, Davis SL. Influence of Body Weight Category on Outcomes in Candidemia Patients Treated With Anidulafungin. J Pharm Pract. 2020 Jul 10;897190020938219. doi: 10.1177/0897190020938219. Epub 2020 Jul 10. PMID: 32648506.
Copy Download .nbib Format: NLM
Deacylation of Echinocandin B by Streptomyces species: a novel method for the production of Echinocandin B nucleus.

3 Biotech

Shivakumar MC, Manohar S, Ishwar B, Raghu P, Savitha J.
PMID: 31696017
3 Biotech. 2019 Nov;9(11):412. doi: 10.1007/s13205-019-1946-7. Epub 2019 Oct 23.

Anidulafungin, a new class of antifungal agent used for the treatment of chronic fungal infections, is derived from Echinocandin B nucleus, an intermediate metabolite of Echinocandin B produced by

Cite
Shivakumar MC, Manohar S, Ishwar B, et al. Deacylation of Echinocandin B by Streptomyces species: a novel method for the production of Echinocandin B nucleus. 3 Biotech. 2019;9(11):412doi: 10.1007/s13205-019-1946-7.
Shivakumar, M. C., Manohar, S., Ishwar, B., Raghu, P., & Savitha, J. (2019). Deacylation of Echinocandin B by Streptomyces species: a novel method for the production of Echinocandin B nucleus. 3 Biotech, 9(11), 412. https://doi.org/10.1007/s13205-019-1946-7
Shivakumar, M C, et al. "Deacylation of Echinocandin B by Streptomyces species: a novel method for the production of Echinocandin B nucleus." 3 Biotech vol. 9,11 (2019): 412. doi: https://doi.org/10.1007/s13205-019-1946-7
Shivakumar MC, Manohar S, Ishwar B, Raghu P, Savitha J. Deacylation of Echinocandin B by Streptomyces species: a novel method for the production of Echinocandin B nucleus. 3 Biotech. 2019 Nov;9(11):412. doi: 10.1007/s13205-019-1946-7. Epub 2019 Oct 23. PMID: 31696017; PMCID: PMC6811456.
Copy Download .nbib Format: NLM
Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation.

Infection and drug resistance

Yeoh SF, Lee TJ, Chew KL, Lin S, Yeo D, Setia S.
PMID: 29881298
Infect Drug Resist. 2018 May 30;11:805-819. doi: 10.2147/IDR.S165676. eCollection 2018.

No abstract available.

Cite
Yeoh SF, Lee TJ, Chew KL, et al. Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation. Infect Drug Resist. 2018;11:805-819doi: 10.2147/IDR.S165676.
Yeoh, S. F., Lee, T. J., Chew, K. L., Lin, S., Yeo, D., & Setia, S. (2018). Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation. Infection and drug resistance, 11805-819. https://doi.org/10.2147/IDR.S165676
Yeoh, Siang Fei, et al. "Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation." Infection and drug resistance vol. 11 (2018): 805-819. doi: https://doi.org/10.2147/IDR.S165676
Yeoh SF, Lee TJ, Chew KL, Lin S, Yeo D, Setia S. Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation. Infect Drug Resist. 2018 May 30;11:805-819. doi: 10.2147/IDR.S165676. eCollection 2018. PMID: 29881298; PMCID: PMC5985852.
Copy Download .nbib Format: NLM
Assessment of nonreleasing antifungal surface coatings bearing covalently attached pharmaceuticals.

Biointerphases

Naderi J, Griesser HJ, Coad BR.
PMID: 34794317
Biointerphases. 2021 Nov 18;16(6):061001. doi: 10.1116/6.0001099.

There are many reports of antimicrobial coatings bearing immobilized active agents on surfaces; however, strong analytical evidence is required to verify that the agents are indeed covalently attached to the surface. In the absence of such evidence, antimicrobial activity...

Cite
Naderi J, Griesser HJ, Coad BR. Assessment of nonreleasing antifungal surface coatings bearing covalently attached pharmaceuticals. Biointerphases. 2021;16(6):061001doi: 10.1116/6.0001099.
Naderi, J., Griesser, H. J., & Coad, B. R. (2021). Assessment of nonreleasing antifungal surface coatings bearing covalently attached pharmaceuticals. Biointerphases, 16(6), 061001. https://doi.org/10.1116/6.0001099
Naderi, Javad, et al. "Assessment of nonreleasing antifungal surface coatings bearing covalently attached pharmaceuticals." Biointerphases vol. 16,6 (2021): 061001. doi: https://doi.org/10.1116/6.0001099
Naderi J, Griesser HJ, Coad BR. Assessment of nonreleasing antifungal surface coatings bearing covalently attached pharmaceuticals. Biointerphases. 2021 Nov 18;16(6):061001. doi: 10.1116/6.0001099. PMID: 34794317.
Copy Download .nbib Format: NLM
Susceptibility testing of Prototheca bovis isolates from cases of bovine mastitis using the CLSI reference broth microdilution method and the Sensititre YeastOne colorimetric panel.

Medical mycology

Álvarez-Pérez S, Anega B, Díaz-de-Tuesta JA, González-Martín JV, Riesgo-Martínez M, García ME, Blanco JL.
PMID: 34643716
Med Mycol. 2021 Dec 03;59(12):1257-1261. doi: 10.1093/mmy/myab063.

A total of 62 Prototheca bovis isolates from cases of bovine mastitis were tested for susceptibility to different antifungal compounds by the Clinical and Laboratory Standards Institute (CLSI) reference microdilution method and a commercial colorimetric microdilution panel (Sensititre YeastOne)....

Cite
Álvarez-Pérez S, Anega B, Díaz-de-Tuesta JA, et al. Susceptibility testing of Prototheca bovis isolates from cases of bovine mastitis using the CLSI reference broth microdilution method and the Sensititre YeastOne colorimetric panel. Med Mycol. 2021;59(12):1257-1261doi: 10.1093/mmy/myab063.
Álvarez-Pérez, S., Anega, B., Díaz-de-Tuesta, J. A., González-Martín, J. V., Riesgo-Martínez, M., García, M. E., & Blanco, J. L. (2021). Susceptibility testing of Prototheca bovis isolates from cases of bovine mastitis using the CLSI reference broth microdilution method and the Sensititre YeastOne colorimetric panel. Medical mycology, 59(12), 1257-1261. https://doi.org/10.1093/mmy/myab063
Álvarez-Pérez, Sergio, et al. "Susceptibility testing of Prototheca bovis isolates from cases of bovine mastitis using the CLSI reference broth microdilution method and the Sensititre YeastOne colorimetric panel." Medical mycology vol. 59,12 (2021): 1257-1261. doi: https://doi.org/10.1093/mmy/myab063
Álvarez-Pérez S, Anega B, Díaz-de-Tuesta JA, González-Martín JV, Riesgo-Martínez M, García ME, Blanco JL. Susceptibility testing of Prototheca bovis isolates from cases of bovine mastitis using the CLSI reference broth microdilution method and the Sensititre YeastOne colorimetric panel. Med Mycol. 2021 Dec 03;59(12):1257-1261. doi: 10.1093/mmy/myab063. PMID: 34643716.
Copy Download .nbib Format: NLM
In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against .

Pharmaceutics

Caballero U, Eraso E, Quindós G, Jauregizar N.
PMID: 34575409
Pharmaceutics. 2021 Aug 25;13(9). doi: 10.3390/pharmaceutics13091333.

Treatment of invasive infections caused by

Cite
Caballero U, Eraso E, Quindós G, et al. In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against . Pharmaceutics. 2021;13(9)doi: 10.3390/pharmaceutics13091333.
Caballero, U., Eraso, E., Quindós, G., & Jauregizar, N. (2021). In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against . Pharmaceutics, 13(9), . https://doi.org/10.3390/pharmaceutics13091333
Caballero, Unai, et al. "In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against ." Pharmaceutics vol. 13,9 (2021). doi: https://doi.org/10.3390/pharmaceutics13091333
Caballero U, Eraso E, Quindós G, Jauregizar N. In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against . Pharmaceutics. 2021 Aug 25;13(9). doi: 10.3390/pharmaceutics13091333. PMID: 34575409; PMCID: PMC8468219.
Copy Download .nbib Format: NLM
DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis.

Antimicrobial agents and chemotherapy

Ambati S, Pham T, Lewis ZA, Lin X, Meagher RB.
PMID: 34633846
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0146721. doi: 10.1128/AAC.01467-21. Epub 2021 Oct 11.

Candida albicans causes life-threatening disseminated candidiasis. Individuals at greatest risk have weakened immune systems. An outer cell wall, exopolysaccharide matrix, and biofilm rich in oligoglucans and oligomannans help

Cite
Ambati S, Pham T, Lewis ZA, et al. DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis. Antimicrob Agents Chemother. 2021;66(1):e0146721doi: 10.1128/AAC.01467-21.
Ambati, S., Pham, T., Lewis, Z. A., Lin, X., & Meagher, R. B. (2022). DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis. Antimicrobial agents and chemotherapy, 66(1), e0146721. https://doi.org/10.1128/AAC.01467-21
Ambati, Suresh, et al. "DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis." Antimicrobial agents and chemotherapy vol. 66,1 (2022): e0146721. doi: https://doi.org/10.1128/AAC.01467-21
Ambati S, Pham T, Lewis ZA, Lin X, Meagher RB. DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0146721. doi: 10.1128/AAC.01467-21. Epub 2021 Oct 11. PMID: 34633846.
Copy Download .nbib Format: NLM
Functional expression of an echinocandin B deacylase from Actinoplanes utahensis in Escherichia coli.

International journal of biological macromolecules

Zou SP, Han X, Zhu HY, Sheng Q, Tang H, Liu ZQ, Zheng YG.
PMID: 34339787
Int J Biol Macromol. 2021 Sep 30;187:850-857. doi: 10.1016/j.ijbiomac.2021.07.146. Epub 2021 Jul 30.

Echinocandin B deacylase (ECBD) from Actinoplanes utahensis can be applied to produce echinocandin B nucleus (ECBN), an essential intermediate of the echinocandins antifungal drugs such as anidulafungin. To date, the expression of ECBD has been limited to Streptomyces. To...

Cite
Zou SP, Han X, Zhu HY, et al. Functional expression of an echinocandin B deacylase from Actinoplanes utahensis in Escherichia coli. Int J Biol Macromol. 2021;187:850-857doi: 10.1016/j.ijbiomac.2021.07.146.
Zou, S. P., Han, X., Zhu, H. Y., Sheng, Q., Tang, H., Liu, Z. Q., & Zheng, Y. G. (2021). Functional expression of an echinocandin B deacylase from Actinoplanes utahensis in Escherichia coli. International journal of biological macromolecules, 187850-857. https://doi.org/10.1016/j.ijbiomac.2021.07.146
Zou, Shu-Ping, et al. "Functional expression of an echinocandin B deacylase from Actinoplanes utahensis in Escherichia coli." International journal of biological macromolecules vol. 187 (2021): 850-857. doi: https://doi.org/10.1016/j.ijbiomac.2021.07.146
Zou SP, Han X, Zhu HY, Sheng Q, Tang H, Liu ZQ, Zheng YG. Functional expression of an echinocandin B deacylase from Actinoplanes utahensis in Escherichia coli. Int J Biol Macromol. 2021 Sep 30;187:850-857. doi: 10.1016/j.ijbiomac.2021.07.146. Epub 2021 Jul 30. PMID: 34339787.
Copy Download .nbib Format: NLM
Epidemiology of echinocandin resistance in .

Current fungal infection reports

Grossman NT, Chiller TM, Lockhart SR.
PMID: 29780439
Curr Fungal Infect Rep. 2014 Dec;8(4):243-248. doi: 10.1007/s12281-014-0209-7. Epub 2014 Sep 21.

Echinocandins are the newest antifungal agents approved for use in treating

Cite
Grossman NT, Chiller TM, Lockhart SR. Epidemiology of echinocandin resistance in . Curr Fungal Infect Rep. 2014;8(4):243-248doi: 10.1007/s12281-014-0209-7.
Grossman, N. T., Chiller, T. M., & Lockhart, S. R. (2014). Epidemiology of echinocandin resistance in . Current fungal infection reports, 8(4), 243-248. https://doi.org/10.1007/s12281-014-0209-7
Grossman, Nina T, et al. "Epidemiology of echinocandin resistance in ." Current fungal infection reports vol. 8,4 (2014): 243-248. doi: https://doi.org/10.1007/s12281-014-0209-7
Grossman NT, Chiller TM, Lockhart SR. Epidemiology of echinocandin resistance in . Curr Fungal Infect Rep. 2014 Dec;8(4):243-248. doi: 10.1007/s12281-014-0209-7. Epub 2014 Sep 21. PMID: 29780439; PMCID: PMC5956517.
Copy Download .nbib Format: NLM
Successful Treatment of Azole-Resistant Candida Esophagitis in an Immunocompromised Pregnant Woman Using Anidulafungin.

The Annals of pharmacotherapy

Blackwell CO, Sheth AN, Nguyen ML, Badell ML.
PMID: 28660773
Ann Pharmacother. 2017 Nov;51(11):1033-1034. doi: 10.1177/1060028017717998. Epub 2017 Jun 29.

No abstract available.

Cite
Blackwell CO, Sheth AN, Nguyen ML, et al. Successful Treatment of Azole-Resistant Candida Esophagitis in an Immunocompromised Pregnant Woman Using Anidulafungin. Ann Pharmacother. 2017;51(11):1033-1034doi: 10.1177/1060028017717998.
Blackwell, C. O., Sheth, A. N., Nguyen, M. L., & Badell, M. L. (2017). Successful Treatment of Azole-Resistant Candida Esophagitis in an Immunocompromised Pregnant Woman Using Anidulafungin. The Annals of pharmacotherapy, 51(11), 1033-1034. https://doi.org/10.1177/1060028017717998
Blackwell, Conner O, et al. "Successful Treatment of Azole-Resistant Candida Esophagitis in an Immunocompromised Pregnant Woman Using Anidulafungin." The Annals of pharmacotherapy vol. 51,11 (2017): 1033-1034. doi: https://doi.org/10.1177/1060028017717998
Blackwell CO, Sheth AN, Nguyen ML, Badell ML. Successful Treatment of Azole-Resistant Candida Esophagitis in an Immunocompromised Pregnant Woman Using Anidulafungin. Ann Pharmacother. 2017 Nov;51(11):1033-1034. doi: 10.1177/1060028017717998. Epub 2017 Jun 29. PMID: 28660773.
Copy Download .nbib Format: NLM
Anidulafungin: advantage for the newcomer?.

Expert review of clinical pharmacology

Rüping MJ, Vehreschild JJ, Farowski F, Cornely OA.
PMID: 24422646
Expert Rev Clin Pharmacol. 2008 Mar;1(2):207-16. doi: 10.1586/17512433.1.2.207.

Anidulafungin is the most recently approved compound of the echinocandin antifungal class. Its mode of action is the noncompetitive inhibition of β-(1,3)-D-glucan synthesis. Potent fungicidal activity has been demonstrated against many Candida spp., including non-albicansCandida spp. and fluconazole-resistant strains,...

Cite
Rüping MJ, Vehreschild JJ, Farowski F, et al. Anidulafungin: advantage for the newcomer?. Expert Rev Clin Pharmacol. 2008;1(2):207-16doi: 10.1586/17512433.1.2.207.
Rüping, M. J., Vehreschild, J. J., Farowski, F., & Cornely, O. A. (2008). Anidulafungin: advantage for the newcomer?. Expert review of clinical pharmacology, 1(2), 207-16. https://doi.org/10.1586/17512433.1.2.207
Rüping, Maria J, et al. "Anidulafungin: advantage for the newcomer?." Expert review of clinical pharmacology vol. 1,2 (2008): 207-16. doi: https://doi.org/10.1586/17512433.1.2.207
Rüping MJ, Vehreschild JJ, Farowski F, Cornely OA. Anidulafungin: advantage for the newcomer?. Expert Rev Clin Pharmacol. 2008 Mar;1(2):207-16. doi: 10.1586/17512433.1.2.207. PMID: 24422646.
Copy Download .nbib Format: NLM
Candida utilis catheter-related bloodstream infection.

Medical mycology case reports

Scoppettuolo G, Donato C, De Carolis E, Vella A, Vaccaro L, La Greca A, Fantoni M.
PMID: 25473600
Med Mycol Case Rep. 2014 Nov 04;6:70-2. doi: 10.1016/j.mmcr.2014.10.003. eCollection 2014 Oct.

Central venous catheter-related fungemia are increasing in the last years, also due to rare fungi. We report the case of a Candida utilis catheter-related bloodstream infection in a patient with metastatic carcinoma of the bladder and a long term...

Cite
Scoppettuolo G, Donato C, De Carolis E, et al. Candida utilis catheter-related bloodstream infection. Med Mycol Case Rep. 2014;6:70-2doi: 10.1016/j.mmcr.2014.10.003.
Scoppettuolo, G., Donato, C., De Carolis, E., Vella, A., Vaccaro, L., La Greca, A., & Fantoni, M. (2014). Candida utilis catheter-related bloodstream infection. Medical mycology case reports, 670-2. https://doi.org/10.1016/j.mmcr.2014.10.003
Scoppettuolo, Giancarlo, et al. "Candida utilis catheter-related bloodstream infection." Medical mycology case reports vol. 6 (2014): 70-2. doi: https://doi.org/10.1016/j.mmcr.2014.10.003
Scoppettuolo G, Donato C, De Carolis E, Vella A, Vaccaro L, La Greca A, Fantoni M. Candida utilis catheter-related bloodstream infection. Med Mycol Case Rep. 2014 Nov 04;6:70-2. doi: 10.1016/j.mmcr.2014.10.003. eCollection 2014 Oct. PMID: 25473600; PMCID: PMC4246400.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 94 entries